01—Abstract
Summary
Summary of the 8-K filed July 28, 2026. Cited figures are marked; the original filing is the authoritative source.
Centene reported second-quarter 2026 results on July 28, 2026, with GAAP diluted EPS of $2.19a and adjusted diluted EPS of $2.51, compared with a GAAP loss of $(0.51) and adjusted loss of $(0.16) in the prior-year quarter.
Total revenues rose to $53.6 billionb from $48.7 billion, and premium and service revenues grew 4% to $44.4 billion. The health benefits ratio improved sharply to 89.6% from 93.0%, driven by Marketplace pricing and risk transfer, Medicaid rate increases, and a favorable Medicare outcome, with Commercial HBR falling to 79.2%. Management raised full-year 2026 guidance: GAAP diluted EPS is now greater than $3.11 and adjusted diluted EPS greater than $4.80, with total revenue guidance increased by $6.0 billion to $193.5–$197.5 billion.
Management noted roughly $0.50c of non-recurring items in the guidance increase, a point investors should weigh when judging the sustainability of the raised outlook. Balance sheet and cash generation also strengthened. Operating cash flow for the quarter was $3.6 billion, and cash, investments and restricted deposits reached $44.8 billion.
Total debt declined to $16.1 billiond after $260 million of senior note repurchases, and debt-to-capitalization fell to 41.6% from 46.5% at year-end 2025. Membership continued to shift: Marketplace enrollment dropped to 3.5 million from 5.9 million a year earlier, while PDP membership grew to 8.8 million. Total at-risk membership declined about 8% year over year to 25.9 million, reflecting deliberate repricing and exits in Marketplace.
Separately, director Kenneth Burdick resigned effective July 28, 2026, and the board appointed Paul Diaz, a healthcare private equity managing partner and former CEO of Myriad Genetics and Kindred Healthcare, to fill the vacancy. The board change is routine and not tied to any disagreement with the company, so it is unlikely to affect the investment case on its own.
02—Key points
Key Highlights
- GAAP diluted EPS of $2.19 and adjusted diluted EPS of $2.51 for Q2 2026, versus a GAAP loss of $(0.51) in Q2 2025.
- Consolidated HBR improved to 89.6% from 93.0%, with Commercial HBR at 79.2%, Medicare at 89.5%, and Medicaid at 93.9%.
- FY2026 guidance raised: GAAP diluted EPS above $3.11 and adjusted diluted EPS above $4.80; total revenue guidance increased by $6.0 billion to $193.5–$197.5 billion.
- Roughly $0.50 of non-recurring items contributed to the guidance increase, which management attributes partly to one-time Medicare and Commercial benefits.
- Operating cash flow of $3.6 billion in Q2; cash, investments and restricted deposits of $44.8 billion; debt-to-capitalization improved to 41.6%.
- Total at-risk membership fell to 25.9 million (down about 8% YoY) as Marketplace enrollment shrank from 5.9 million to 3.5 million, while PDP grew to 8.8 million.
- Board change: Kenneth Burdick resigned effective July 28, 2026; Paul Diaz was appointed as a director and to the Audit and Quality & Compliance Committees.
03—Questions
Frequently Asked Questions
Why did Centene's profitability improve so much year over year?
The improvement came mainly from a lower HBR (89.6% vs. 93.0%), driven by better Marketplace pricing and risk transfer, Medicaid rate increases to offset medical cost trend, and a favorable Medicare resolution of 2025 programmatic items. The prior-year quarter also included a Medicare premium deficiency reserve that was not repeated in 2026, and lower Marketplace membership, which carries a higher SG&A ratio, helped leverage expenses.
How much of the raised 2026 guidance is recurring?
Management said the guidance increase reflects underlying business strength but includes approximately $0.50 of non-recurring items in the Medicare and Commercial segments. Investors should separate these one-time benefits from the core run-rate when extrapolating second-half earnings.
Is Centene's balance sheet getting stronger?
Yes. Total debt fell to $16.1 billion after $260 million of note repurchases, the $4.0 billion revolver was undrawn at quarter end, and debt-to-capitalization dropped from 46.5% at year-end 2025 to 41.6%. Stockholders' equity rose to $22.6 billion, and cash, investments and restricted deposits grew to $44.8 billion, though only $715 million was available for general corporate use.
Why did membership decline, and is that a concern?
The decline was concentrated in Marketplace, which fell from 5.9 million to 3.5 million year over year, and in Medicaid, where Traditional and High Acuity membership both fell. Management appears to be deliberately prioritizing pricing discipline and margin over enrollment growth. The shift toward lower-cost PDP membership (up to 8.8 million) partly offsets the decline in revenue per member.
Does the board change signal any governance concern?
The filing states that Mr. Burdick's resignation was not due to any dispute or disagreement with the company or its board, and it is described as a personal and retirement decision. The appointment of Paul Diaz, who has public-company and healthcare executive experience, is a routine refresh and does not by itself indicate a change in strategy.
04—Continue